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Abstract: Anti-angiogenic agents, such as the multi-tyrosine kinase inhibitor sunitinib, are key first
line therapies for metastatic clear cell renal cell carcinoma (ccRCC), but their mechanism of action
is not fully understood. Here, we take steps towards validating a computational prediction based
on differential transcriptome network analysis that phosphorylated adapter RNA export protein
(PHAX) is associated with sunitinib drug treatment. The regulatory impact factor differential network
algorithm run on patient tissue samples suggests PHAX is likely an important regulator through
changes in genome-wide network connectivity. Immunofluorescence staining of patient tumours
showed strong localisation of PHAX to the microvasculature consistent with the anti-angiogenic
effect of sunitinib. In normal kidney tissue, PHAX protein abundance was low but increased with
tumour grade (G1 vs. G3/4; p < 0.01), consistent with a possible role in cancer progression. In organ
culture, ccRCC cells had higher levels of PHAX protein expression than normal kidney cells, and
sunitinib increased PHAX protein expression in a dose dependent manner (untreated vs. 100 µM;
p < 0.05). PHAX knockdown in a ccRCC organ culture model impacted the ability of sunitinib to
cause cancer cell death (p < 0.0001 untreated vs. treated), suggesting a role for PHAX in mediating
the efficacy of sunitinib.
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1. Introduction
Renal cell cancer (RCC) is the most lethal urological malignancy and the most common type
of kidney cancer in adults [1]. Clear cell RCC (ccRCC) is the most common histological subtype,
comprising 85% of all cases. The underlying genetic aberrations of ccRCC are becoming increasingly
well understood [2]. Von Hippel Lindau (VHL) mutation is the key driver mutation in >90% of
ccRCCs, and hence targeting this axis was thought to exploit the disease’s “Achilles heel.” As such,
metastatic ccRCC management has been dominated by treatment with anti-angiogenic agents, such as
the multi-tyrosine kinase inhibitor sunitinib [3]. Although 70% of patients show a therapeutic tumour
response to sunitinib, all patients eventually develop acquired drug resistance. Sunitinib’s mechanism
is via endothelial targeting [4], but the impact on RCC epithelial cells, the variable efficacy between
patients, and the development of tumour resistance are incompletely understood [5].
One approach for developing a molecular understanding of a disease state and its interaction with
drug treatments is to make use of genome-wide transcriptome screening methods. These approaches
can simultaneously quantify the entire cohort of mRNA (and other classes of RNA) expressed in a
given tissue in a particular set of biological circumstances which makes them very powerful in pathway
quantitation. By way of contrast, proteomic approaches provide only limited coverage out of the
potentially ≈1 million total human proteins in a complex tissue sample [6,7]. This is in part due to
issues with sensitivity, handling an enormous dynamic range and biological interpretation that is
complicated by method of acquisition and the particular data analysis platform [8]. On the other hand,
transcriptomic data are truly genome-wide and therefore uniquely well positioned to underpin basic
molecular discovery in an unbiased manner. The foundational analytical approach when exploring
transcriptome data is to compare mRNA levels with each other across two or more treatments,
producing a list of differentially expressed (DE) genes. This DE list can then be interrogated in the
context of known biological pathways and processes, using functional enrichment web tools such as
Gorilla [9] and DAVID [10].
The basic DE approach has limitations because many proteins are differentially activated
irrespective of any change in their mRNA levels. Consequently, a reliance on mRNA DE may
overlook those genes which behave very differently across states at the protein level, due to one of
any number of post-transcriptional mechanisms that could be at play [11]. Here, we have made use
of a differential network algorithm called regulatory impact factor (RIF) analysis, which asks the
following question of the transcriptome data: “Following sunitinib treatment, which molecule changes
its position in the RCC regulatory network the most, irrespective of its own mRNA expression level?”
In this context, we find the answer to this question to be the mRNA encoding the protein PHAX.
The role of the PHAX protein is subsequently investigated in real patient samples and a tractable
in vitro model of RCC. Our data supports an association between sunitinib efficacy and PHAX in vitro.
2. Results
2.1. Regulatory Impact Factor Analysis
It is evident from examination of the rocket plot or minus-average (MA) plot (Figure 1A) that the
mRNA encoding PHAX is neither abundant nor differentially expressed across the two treatments and
would not be identified as being of functional interest based on an exclusive reliance on DE. RIF1 and
RIF2 scores were plotted and manually explored for outlier mRNA molecules (Figure 1B). Most of the
mass of the data are centred close to 0, implying that the majority of molecules are not differentially
networked between sunitinib treated and control samples. Most molecules would therefore be
predicted to perform the same respective functions in the same manner across the two groups.
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Figure 1. PHAX mRNA expression in samples of renal cell cancer (RCC) tissue from patients with 
metastatic RCC (mRCC) either treated with sunitinib or untreated controls patients. PHAX mRNA is 
moderately abundant and not differentially expressed across the two treatment groups (A). However, 
we found using the regulatory impact factor (RIF) algorithm that PHAX mRNA is highly differentially 
connected between networks constructed using the two groups (B). The extreme RIF score for 
differential networking implies that the encoded protein PHAX behaves very differently in the drug 
treated versus control samples even though its own mRNA expression level has remained largely 
unchanged. 
However, there are a small number of molecules that are highly differentially connected (based 
on global patterns of high differential co-expression across the two treatments) according to both 
versions of RIF. Of the annotated probes, PHAX received the highest combined RIF score (Table 1; 
Supplementary data File 1) based on its extreme position in the top left quadrant of the plot. A 
number of unannotated probes, such as LOC100130441 and LOC641522, also received extreme scores. 
We elected to focus on experimentally characterising the role of PHAX given an unambiguous 
annotation of this probe to an encoded protein. 
  
Figure 1. PHAX mRNA expression in samples of renal cell cancer (RCC) tissue from patients with
metastatic RCC (mRCC) either treated with sunitinib or untreated controls patients. PHAX mRNA is
moderately abundant and not differ ntially expressed across the two treatment groups (A). owever,
we found using the regulat ry impact factor (RIF) algorithm that PHAX mRNA is highly differentially
connected between networks constructed using the two groups (B). The extreme RIF score for differential
networking implies that the encoded protein PHAX behaves very differently in the drug treated versus
control samples even though its own mRNA expression level has remained largely unchanged.
However, there are a s all number of molecules that are highly differentially connected (based on
global patterns of high differential co-expression across the two treatments) according to both versions
of RIF. Of the annotated probes, PHAX received the highest combined RIF score (Table 1; Supplementary
data File 1) based on its extreme position in the top left quadrant of the plot. A number of unannotated
pro es, such as LOC100130441 and LOC641522, also received extreme scores. We elected to focus on
experimentally characterising the role of PHAX given an unambiguous annotation of this probe to an
encoded protein.
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Table 1. The top 10 most differentially connected probes in sunitinib treated versus control kidney
cancer cells. Ranking was performed on the absolute average of RIF1 and RIF2 scores. PHAX was
awarded the highest combined RIF scores of the annotated probes.
Probe Gene RIF1 Score RIF2 Score Combined RIF Score
ILMN_3260932 LOC100130441 −2.74 2.98 5.72
ILMN_2190779 PHAX −2.37 3.18 5.55
ILMN_2141030 LOC641522 −2.16 3.21 5.38
ILMN_2110751 CHRNA5 −3.79 1.50 5.30
ILMN_1787314 ALS2CR14 −2.99 2.28 5.27
ILMN_2169839 CNBP −3.85 1.34 5.20
ILMN_3179148 LOC100128096 −1.66 3.50 5.17
ILMN_2053536 RHBDL2 −3.54 1.58 5.12
ILMN_3279960 LOC642784 −3.04 2.03 5.08
ILMN_1680774 LOC730994 −2.54 2.52 5.07
To further interrogate the functional basis of PHAX’s potential involvement in mediating the
impact of sunitinib treatment in RCC tissue we evaluated the pairwise relationships between PHAX
and the 1279 DE targets under consideration in more detail. For each target gene we calculated both
its phenotypic impact factor (PIF, the product of its DE and average abundance when comparing
sunitinib treated versus control RCC tissue) and its differential co-expression to PHAX (again, sunitinib
treated versus control RCC tissue). We then ranked the products of those two metrics (full data
set in Supplementary data File 2). Because we used absolute differential co-expression values for
the purposes of generating this list, the sign of the product relates to the direction of DE; i.e.,
a positive value implies higher expression in sunitinib treated samples, and negative implies lower
expression in sunitinib treated samples. The extreme negative values enriched for ribosomal proteins
(p = 3.92 × 10−17; FDR Q value = 2.54 × 10−13) including, but not limited to RPL8, RPL23, RPL38, RPL30,
RPS14, and RPS16. The extreme positive values enriched for small nuclear RNAs (p = 0.0000728;
FDR Q value= 0.049) including, but not limited to: RN7SK, RN5S9, and RNU4-1. PHAX is known to
regulate this class of molecule [12]. In all cases, functional enrichment was assessed by hypergeometric
statistics after importing single ranked lists into the GOrilla webtool [9]. This analysis allows more
accurate identification of the molecular pathways predicted to be modulated by PHAX during sunitinib
treatment and drive the extreme RIF output scores PHAX was awarded.
2.2. PHAX Protein Expression Is Increased in High Grade ccRCC Tumours As Compared to Adjacent Normal
Kidney (NK) Cells
Prior to further evaluating the functional effects of PHAX on sunitinib activity in ccRCC, we
wanted to determine that PHAX was a relevant protein in this malignancy. As such, we examined
the PHAX expression in ccRCC and adjacent NK tissue. NK showed negligible PHAX expression
(Figure 2A); PHAX was mildly increased in ccRCC grade 1 tumours (* p < 0.05) (Figure 2B). In contrast,
a moderate signal was detected in ccRCC grade 2 (** p < 0.001), which was more pronounced in
high-grade tumours (grades 2–4) (*** p < 0.0001) (Figure 2C–E). The pattern of staining was mainly
cytoplasmic (Figure 2D,E), with nuclear patterns being seen in some tubular epithelial cells (TECs) and
within the glomeruli capillary wall (Figure 2C). Staining intensity presented as digital histological score
(D-HSCORE) showed a difference in PHAX expression between ccRCC grades and NK (Figure 2F).
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Figure 2. PHAX protein expression in clear cell renal cell carcinoma (ccRCC) grades 1–4 and adjacent 
normal kidney (NK) cells. (A) NK cells show a negligible level of PHAX expression, with a mild signal 
detected in some tubular epithelial cells (t) in ccRCC grade 1 (B), increasing in intensity and frequency 
in high grade tumours (G2–G4) within the intertitial capillary network (red arrow) and in sheets of 
tumour cells (arrows), both cytoplasmic and nuclear patternx (C–E). Signal intensity is presented as a 
digital histological score (D-HSCORE) with high grade tumours showing statistically significantly 
increased expression for PHAX (F). (NK vs. G1—(*P < 0.05), NK vs. G2—(** P < 0.01), NK vs. G3 or 
G4—(*** P < 0.0001), G1 vs. G2—(* P < 0.05), G1 vs. G3/G4—(** P < 0.01), G2 vs. G3—(**P < 0.01), G3 
vs. G4—(ns)). Bars = means + SEMs. N = 3 per group with similar results. Original magnification ×250. 
  
Figure 2. PHAX protein expression in clear cell renal cell carcinoma (ccRCC) grades 1–4 and adjacent
normal kidney (NK) cells. (A) NK cells show a negligible level of PHAX expression, with a mild signal
detected in some tubular epithelial cells (t) in ccRCC grade 1 (B), increasing in intensity and frequency
in high grade tumours (G2–G4) within the intertitial capillary network (red arrow) and in sheets of
tumour cells (arrows), both cytoplasmic and nuclear patternx (C–E). Signal intensity is presented as
a digital histological score (D-HSCORE) with high grade tumours showing statistically significantly
increased expression for PHAX (F). (NK vs. G1—(*p < 0.05), NK vs. G2—(** p < 0.01), NK vs. G3 or
G4—(*** p < 0.0001), G1 vs. G2—(* p < 0.05), G1 vs. G3/G4—(** p < 0.01), G2 vs. G3—(**p < 0.01), G3 vs.
G4—(ns)). Bars = means + SEMs. N = 3 per group with similar results. Original magnification ×250.
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2.3. Sunitinib Induces PHAX Protein Expression in Tumour Cells and Vascular Endothelial Cells in ccRCC
To evaluate the functional effects of PHAX, we turned to an established model system of human
organ culture of ccRCC and NK tissue [13] to gain insight into the effect of sunitinib on PHAX expression.
PHAX expression was analysed by immunofluorescence on sections of organ cultures from grade 2 and
3 ccRCC and NK either left UT or treated with increasing doses of sunitinib (25, 50, 100, and 200 µM)
and co-stained for CK. ccRCC organ cultures that were UT and treated with low dose sunitinib (25 and
50 µM) showed rare to mildly infrequent expression of PHAX in CK-positive tumour cells (Figure 3A).
In contrast, cultures treated with high dose sunitinib (100 and 200 µM) showed a statistically significant
increase expression of PHAX in tumour cells (p < 0.001). PHAX expression was also seen in CK-negative
infiltrating mononuclear cells within tumour and renal parenchyma interstitium in cultures treated
with 100 µM sunitinib (Figure 3A). No signal was detected in a negative control when the primary
antibody to PHAX was replaced by isotype-specific antisera (Figure S1). Parallel cultures treated with
high dose sunitinib (200 µM) and co-immunostained with anti-CD31 showed marked expression of
PHAX in CD31-positive vascular endothelial cells (ECs) in some small and large vessels (Figure 3B).
Staining for PHAX was also seen in infiltrating mononuclear cells and in CD31-negative tumour cells
(Figure 3B). Organ cultures of NK showed a similar pattern of PHAX expression and CK or CD31
but with less intensity and frequency as compared to ccRCC organ cultures (Figures S2 and S3).
Additionally present in NK organ cultures were some CK-positive/PHAX-negative TECs. Images of PHAX
expression in CK-positive tumour cells and CD31-positive ECs were taken in 10 random high-power fields
(×40 magnification) and quantified in an unbiased manner, presented as corrected total fluorescence
(CTF) intensity (Figures 3C and S4). A significant increase in PHAX expression was evident in both
ECs, tumour cells and in TECs in NK with sunitinib exposure in a dose-dependent manner.
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sunitinib, greatly pronounced in cultures treated with high dose sunitinib (100 or 200 µM). Some 
infiltrating mononuclear cells within the interstitium are PHAX-positive and CK-negative (open arrows), and 
some CK-positive tumour cells are PHAX-negative. (B) Parallel sections of 200µM sunitinib-treated ccRCC 
organ cultures co-stained with antibody to CD31 and PHAX show a marked expression of PHAX in 
in CD31positive endothelial cells (arrows), in some infiltrating cells (arrowheads), and in CD31negative 
tumour cells (t). Original magnification ×40. (C). Quantification of mean fluorescence intensity 
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fluorescence of background readings) for PHAX/CK co-expression in tumour cells (NK organ cultures 
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organ cultures (RCCoC)—ns (not significant—UT vs. 25 or 50 µM; × P < 0.001—vs. UT, 25 or 50 µM; ± 
P < 0.05—vs. 100 µM). Bars = mean + SEM. N = 3 per group with similar results. 
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Organ Culture 
We next analysed the effect of sunitinib on cell death and cell proliferation in organ cultures of 
ccRCC and NK. UT ccRCC organ cultures contained sparse TUNEL-positive tumour cells and some 
vascular ECs (4.1 ± 0.2%). A statistically significant increase in cell death was seen among the same 
cell population in cultures treated with 25 µM (33.7 ± 0.6%) or 50 µM sunitinib (47.5 ± 0.3%), which 
Figure 3. Representative confocal images of PHAX protein expression i organ cult res of ccRCC either
untreated or treated with various doses of sunitinib for 1 h in 37 ◦C. (A). Untreated (UT) cultures of
ccRCC show a mild and infrequent expression for PHAX is some tumour cells, positive for cytokeratin
(CK) (shaded arrows). Staining intensity is increased in cultures treated with 25 and 50 µM sunitinib,
greatly pronounced in cultures treated with high dose sunitinib (100 or 200 µM). Some infiltrating
mononuclear cells within the interstitium are PHAX-positive and CK- egative (open arrows), and some
CK-positive tumour cells are PHAX-negative. (B) Parallel sections of 200µM sunitinib-treated ccRCC
organ cultures co-stained with antibody to CD31 and PHAX show a marked expression of PHAX in in
CD31positive endothelial cells (arrows), in some infiltrating cells (arrowheads), and in CD31negative tumour
cells (t). Original magnification ×40. (C). Quantification of mean fluorescence intensity calculated
as corrected total fluorescence (CTF = integrated density—(area of selected cell ×mean fluorescence
of background readings) for PHAX/CK co-expression in tumour cells (NK organ cultures (NKoC)—
**p < 0.05—UT vs. 50 or 100 µM; + p < 0.01—UT vs. 200 µM; ± p < 0.01—100 vs. 200 µM; RCC
organ cultures (RCCoC)—ns (not significant—UT vs. 25 or 50 µM; × p < 0.001—vs. UT, 25 or 50 µM;
± p < 0.05—vs. 100 µM). Bars = mean + SEM. N = 3 per group with similar results.
2.4. Sunitinib Induces Increased Cell Death in Tumour Cells and in Vascular Endothelial Cells in ccRCC
Organ Culture
We next analysed the effect of sunitinib on cell death and cell proliferation in organ cultures of
ccRCC and NK. UT ccRCC organ cultures contained sparse TUNEL-positive tumour cells and some
vascular ECs (4.1 ± 0.2%). A statistically significant increase in cell death was seen among the same cell
population in cultures treated with 25 µM (33.7 ± 0.6%) or 50 µM sunitinib (47.5 ± 0.3%), which was
Biology 2020, 9, 74 8 of 21
even more pronounced in cultures treated with 100 µM (84.1 ± 0.4%) or 200 µM sunitinib (88.5 ± 0.1%).
In contrast, low levels of cell proliferation (detected by immunostaining for pH3S10) was seen in ccRCC
organ cultures treated with low dose sunitinib (25 µM or 50 µM; 3.7 ± 0.1% and 5.2 ± 0.4% respectively)
with a slight increase in cultures treated with high dose sunitinib (100 µM and 200 µM; 5.7 ± 0.7% and
8.2 ± 0.4% respectively). A similar effect of sunitinib-induced cell proliferation was observed in NK
organ cultures, but the effects were more pronounced in ccRCC organ cultures (Figure 4, quantified in
Figure 5A,B). These data are consistent with the interpretation that sunitinib has its effect by inducing
cell death in a dose-dependent manner with minimal effect on cell proliferation in ccRCC.
Biology 2020, 9, x FOR PEER REVIEW 8 of 21 
 
was even more pronounced in cultures treated with 100 µM (84.1 ± 0.4%) or 200 µM sunitinib (88.5 ± 
0.1%). In contrast, low levels of cell proliferation (detected by immunostaining for pH3S10) was seen 
in ccRCC rgan cultures treated with low dose sunitinib (25 µM or 50 µM; 3.7 ± 0.1% nd 5.2 ± 0.4% 
respectively) with a slig t increase in cultures treated with high dose sunitinib (100 µM and 200 µM; 
5.7 ± 0.7% and 8.2 ± 0.4% respectively). A similar effect of sunitinib-induced cell proliferation was 
observed in NK organ cultures, but the effects were more pronounced in ccRCC organ cultures 
(Figure 4, quantified in Figure 5A,B). These data are consistent with the interpretation that sunitinib 
has its effect by inducing cell death in a dose-dependent manner with minimal effect on cell 
proliferation in ccRCC. 
 
Figure 4. Representative confocal images of TUNEL and pH3S10 immunostaining on sections of ccRCC 
and NK organ cultures either untreated or treated with 200µM sunitinib for 1 h at 37 °C. Untreated 
(UT) controls of NK (panels a,b) and ccRCC (e,f) organ cultures showed negligible signals for TUNEL 
or pH3S10. In contrast, sunitinib treatment resulted in an increased signal for TUNEL signal in NK 
organ cultures (c), more pronounced in ccRCC (g). In comparison, sunitinib treatment induced a 
minimal signal for pH3S10 in both organ cultures (d,h). Tumour cells (white arrows), vascular 
endothelial cells (red arrows). N = 3 per group with similar results. Original magnification ×40. 
 
Figure 4. Representative confocal images of TUNEL and pH3S10 immunostaining on sections of ccRCC
and NK organ cultures either untreated or treated with 200µM sunitinib for 1 h at 37 ◦C. Untreated (UT)
controls of NK (panels a,b) and ccRCC (e,f) organ cultures showed negligible signals for TUNEL or
pH3S10. In contrast, sunitinib treatment resulted in an increased signal for TUNEL signal in NK organ
cultures (c), more pronounced in ccRCC (g). In comparison, sunitinib treatment induced a minimal
signal for pH3S10 in both organ cultures (d,h). Tumour cells (white arrows), vascular endothelial cells
(red arrows). N = 3 per group with similar results. Original magnification ×40.
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Figure 5. Effects of different doses of unitinib on cell death (det c ed by TUNEL) and cell proliferation
(detected by a ti-phosphor l ted histone H3S10 immu ostaining) in org n cultures of human normal
kidney d ccRCC organ cultures. N = 3 with similar results. Statistical significance compared to
untreated controls (UT) is indicated as; *p < 0.05, **p < 0.01, ***p < 0.001, +p < 0.0001. NK—**p < 0.01—UT
vs. 25 µM; ***p < 0.01—UT vs. 50 or 100 µM; +p < 0.0001—UT vs. 200 µM. ccRCC—**p < 0.001—UT vs.
25 µM or 50 µM; +p < 0.0001—UT vs. 100 µM or 200 µM. In contrast, sunitinib induced minimal cell
proliferation, significantly only at a high dose as compared to UT controls (NKoC-p < 0.05 (UT vs. 100
or 200 µM); RCCoC-+p < 0.05 (UT vs. 50 or 100 µM and **p < 0.01-UT vs. 200 µM)).
2.5. PHAX siRNA Knockdown Attenuates Sunitinib-Induced Cell Death in ccRCC Organ Culture
We next used siRNA to knockdown PHAX to determine its role in mediating sunitinib’s effect
on grade 2 ccRCC in organ cultures. Successful siRNA-induced knockdown of PHAX protein was
confirmed by immunofluorescence, co-immunostained with CD31 (Figure 6A). Cultures were either
left UT or transfected with a cocktail of PHAX siRNA (containing a mixture of three siRNAs targeting
human PHAX) or with each individual PHAX siRNA (PHAXs iRNA-A, B, and C) or a scrambled
negative control siRNA (NTsiRNA) for 72 h before treatment with 200 µM sunitinib for 1 h at 37 ◦C.
All cultures were then subjected to PHAX immunostaining. As compared to control groups (UT and
NTsiRNA) which showed negligible levels of PHAX expression in CD31positive ECs, in some blood
vessels, (Figure 6A,a), a strong signal was seen in cultures treated with sunitinib alone mainly localised
to tumour cells, CD31positive ECs, and in some infiltrating mononuclear cells (Figure 5A,e). Notably,
sunitinib-induced PHAX expression was markedly reduced in cultures pre-treated with a cocktail of
PHAXs iRNA (Figure 6d) and with individual siRNA dup–A or B) (Figure 6A,e,f) but not C (Figure 6A,g).
Control group (NTsiRNA) treated cultures alone showed minimal expression of PHAX expression
similar to UT cultures (Figure 6A,h), while NTsiRNA in combination with suniti ib (Figure 6A,i)
demonstrated a similar patt rn to cu tures reated wi h sunitinib alone (Figure 6A,c). Positive controls
(transfected with FITC-conjugated siRNA) showed a s rong signal in some infiltrating cells (Figure 6A,j).
Quantification of the mean signal intensity in ccRCC organ cultures transfected with PHAX siRNA vs.
UT is presented as corrected total fluorescence (CTF) intensity in Figure 6B.
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with sunitinib alone (c). Cultures stimulated with NTsiRNA showed a few CD31negative tumour cells 
(arrowheads), and some CD31positive ECs (arrows), (h) while cultures treated with NTsiRNA followed by 
sunitinib show a strong signal for PHAX in CD31positive ECs (shaded arrows), in infiltrating cells (open 
arrows) and some tumour cells (arrowheads) (i). Positive controls using FITC-conjugated siRNA 
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FITC-conjugated siRNA (positive control) prior to treatment with 200 µM sunitinib for 1 h at 37 ◦C.
(A). Untreated (UT) cultures and cultures transfected with PHAXsiRNA alone (without sunitinib)
show mild, infrequent PHAX expression in endothelial cells (ECs) in some blood vessels (arrows) (a,b).
In contrast, cultures treated with 200 µM sunitinib show a strong signal for PHAX in CD31positive
ECs (arrows) and in some CD31negative tumour cells and infiltrating cells (arrowheads) (c). Cultures
pre-treated with a cocktail of PHAXsiRNA (pool of three target-specific siRNAs) (d) or PHAXsiRNA-A
(e) or PHAXsiRNA-B (f) show a diminished level of PHAX expression, with only a mild infrequent
signal seen. PHAXsiRNA-C (g) show the s me intensity and frequ ncy of staini as cultures treated
with sunitinib alone (c). Cultures stimulated with NTs RNA show d a few CD31negative tumour cells
(arrowheads), and some CD31positive ECs (arrows), (h) while cultures treated with NTsiRNA f llowed
by sunitinib show a strong signal for PHAX in CD31positive ECs (shaded arrows), in infiltrating cells
(open arrows) and some tumour cells (arrowheads) (i). Positive controls using FITC-conjugated siRNA
showed green fluorescence-labelled cells within the tissue (arrows), confirming optimisation of siRNA
delivery conditions (j). (B). Quantification of the mean signal intensity for PHAX protein using Image J
calculated as corrected total fluorescence (CTF) in ccRCC organ cultures. Abbreviations: cocktail of
PHAX-siRNA, individual siRNAs duplex components of human PHAX siRNA (siRNA-A, siRNA-B,
and siRNA-C); non-targeting-siRNA (NT of human PHAX siRNA (siRNA-A, siRNA-B, and siRNA-C));
non-targeting-siRNA (NT-siRNA); and FITC-conjugated siRNA (positive control) prior to treatment
with 200 µM sunitinib for 1 h at 37 ◦C. Image J used to measure fluorescence intensity; ata ran ferred
to Microsoft Excel to calculate means + SEM . Sta i tical analysis one-way ANOVA and Bonferroni post
hoc test. *** p < 0.0001—vs. UT or PHAXsiRNA or NTsiRNA alone-treated cultures, + p < 0.001—vs.
sunitinib-treated cultures; ns—not significant.
We next examined the effect of PHAX knockdown on the cell killing effect of sunitinib treatment
in ccRCC organ cultures and adjacent NK (Figure 7A). Following siRNA, all cultures were subjected to
TUNEL to determine cell death. In contrast to UT and PHAX siRNA-treated ccRCC organ cultures,
which showed only a few TUNELpositive tumour cells and vascular ECs (5.0% ± 0.1% and 5.2% ± 0.9%),
cultures treated with high dose sunitinib (200 µM) demonstrated a statistically significant increase in
TUNELpositive cells (84.7% ± 1.2%) (mainly consisting of tumour cells and vascular ECs). Importantly,
cell death induced by sunitinib was significantly attenuated in cultures pre-treated with PHAX siRNA
(37.1% ± 0.49%) or PHAXsiRNA-A (36.2% ± 0.8%) and PHAXsiRNA-B (26.6% ± 0.45%) but not
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PHAXsiRNA-C (83.1% ± 0.9%). Control cultures pre-treated with NTsiRNA showed a similar signal
intensity to UT (3.1% ± 0.2%). Similar effects but to a lesser extent were observed in NK organ cultures
(quantified in Figure 7B): These data indicate that PHAX is an important molecule in mediating sunitinib
effect in ccRCC as its reduced expression renders tumour cells less sensitive to sunitinib-induced
cell death.
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3. Discussion
In line with the observation that the absolute mRNA expression level of a gene does not necessarily
determine its importance in a given biological system, we have computationally predicted that
the molecule PHAX is “rewired” in ccRCC patients treated with sunitinib compared to untreated
patients with a comparable disease profile. Despite a considerable change in apparent network
connectivity following sunitinib treatment, the PHAX mRNA is not differentially expressed in response
to the treatment. The rewiring we observe implies some combination of altered protein abundance,
post-translational modification (such as phosphorylation), or protein behaviour (such as change in
cellular localisation) has occurred in PHAX following sunitinib treatment.
To test whether changes in PHAX contribute to sunitinib’s treatment effect in some way we
undertook a sequence of experiments. These experiments reinforce an association between PHAX and
sunitinib treatment efficacy in kidney cancer cells. We demonstrate that the encoded PHAX protein is
expressed in ccRCC in a functionally relevant manner. Using RNAi in a ccRCC organ culture system
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we have also shown that PHAX protein expression potentiates the efficacy of sunitinib, a key systemic
therapy for the treatment of patients with metastatic ccRCC.
The exact molecular mechanism by which PHAX mediates the effect of sunitinib in controlling
growth of kidney tumours is unclear, but PHAX’s physical co-localisation with the tumour vasculature
suggests a hypothetical link to the drugs known anti-angiogenic properties. Further, we find PHAX
has particularly extreme differential co-expression values to both mRNA encoding ribosomal proteins
(e.g., RPL8, RPL23, and RPL38) and small nuclear RNA (e.g., RN7SK, RN5S9, and RNU4-1), a class
of RNAs that modify the functions of other RNAs, including transfer RNAs. These data imply
that PHAX in part exerts its potentiating impact on the efficacy of sunitinib via these two classes of
molecule. The latter observation is particularly intriguing, as although PHAX is not a particularly well
characterised protein, its function has previously been linked to the biology of small nuclear RNAs
through mediation of nuclear export [14]. Further, in general terms, aberrations in the expression of
small nucleolar RNA have previously been linked to cancer phenotypes [15].
The analyses presented in this study have a number of compelling aspects that are of diverse utility.
We have used and taken steps towards functionally validating in the setting of cancer biology a novel
post-genomic systems biology analysis technique called RIF [16,17]. Differential connectivity as defined
by RIF allows predictions of molecular interactions that are of potential functional importance to
augmenting the more commonly utilised differential expression assessments. Differential connectivity
is important because much functional regulation occurs post-translationally, such as ligand binding,
co-factor binding, and cellular localisation.
In a different cancer context, a previous comparative analysis of a range of computational
approaches for the identification of key transcriptional regulators showed that, while all methods were
able to identify breast cancer relevant regulators, only RIF1 and RIF2 identified regulators with direct
connections to ER+ breast cancer [18]. In the case of sunitinib treated RCC tissue, an exclusive reliance
on DE of the screened mRNA would have completely overlooked the substantial impact we found the
encoded PHAX protein has on the phenotype of interest. Based on the differential connectivity results,
we utilised an organ culture model system designed to mirror the human situation to evaluate the
functional effects of PHAX in vitro; i.e., cultured ccRCC tissue treated with sunitinib.
We have established that the PHAX protein was upregulated in ccRCCs of increasing grade.
This implies PHAX protein abundance may have some prognostic value and/or is somehow relevant in
the progression of the untreated disease. Then, we demonstrated that PHAX protein expression in ECs,
TECs, and tumour cells was increased by sunitinib in the organ cultures in a dose-dependent manner.
Finally, by knocking down PHAX using siRNA, we were able to evaluate the interplay between the
cell killing effect of sunitinib and the induction of PHAX protein expression. We successfully knocked
down PHAX protein and showed that this reduction of expression resulted in a significantly reduced
efficacy of sunitinib in the in vitro model. The use of siRNA in a ccRCC organ culture system represents
a valuable experimental platform for future manipulations of ccRCC tissue at the molecular level.
We are aware of several limitations of this research. Tumour tissue used in the organ culture
studies was donated by patients with localised ccRCC having surgery, as opposed to the metastatic
ccRCC samples used in the original clinical trial cohort providing the gene expression results for
differential connectivity analysis. Sunitinib activity is most relevant on distant metastatic tumour
deposits, as these are the lethal lesions; nonetheless, this class of agent is known to be active on localised
ccRCC, and hence the use of this tissue is considered acceptable [19]. Furthermore, we cannot be
categorical about the interplay between PHAX modulation and efficacy of sunitinib therapy in patients
or the role of PHAX protein expression/behaviour in the development of drug resistance. For example,
we do not know whether the observed increased abundance of PHAX protein in higher grade tumours
mediates an effect on sunitinib responsiveness. This sort of question would require further evaluation
in samples from a clinical trial.
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The systemic therapy options for advanced RCC are rapidly evolving, with combination
immunotherapy becoming a first-line treatment option in intermediate and poor-risk patients [20].
However, tyrosine kinase inhibitors such as sunitinib are likely to remain important agents for the
treatment of metastatic ccRCC, either as monotherapies or parts of combination therapies. The results
from this study show that PHAX protein expression enhances the therapeutic effect of sunitinib in
novel in vitro models. Methods of modulation of PHAX could be evaluated to determine if improved
efficacy of sunitinib can be achieved.
4. Methods
4.1. Antibodies and Reagents
Rabbit anti-PHAX antibody (catalogue number ab171321), mouse anti-phosphorylated histone
H3S10 (pH3S10) (catalogue number ab14955), and rabbit anti-phosphorylated histone H3S10 (pH3S10)
(catalogue number ab5176) were all from Abcam Biotechnology, Cambridge, UK. Mouse anti-CD31
(PECAM1, 89C2; catalogue number 3528) and Hoechst-33342 were from Thermo Fisher Scientific,
Renfrew, UK. Mouse anti-Cytokeratin (catalogue number VP-c420), TUNEL-label (dUTP−FITC)
(catalogue number 11767291910), and terminal transferase enzyme (TdT) (catalogue number
03333566001) were from Roche Diagnostics Ltd., Burgess Hill, UK. Anti-mouse-Cytokeratin (catalogue
number sc-15367), human PHAX siRNA (a pool of 3 targeted-specific 19-25nts siRNAs (cat: sc-106785),
individual siRNA duplex components (cat: sc-106785A; sc-106785B and sc-106785C), control siRNA
(Fluorescein Conjugate)-A (sc-36869), and control siRNA-A (sc-37007) were all from Santa Cruz
Biotechnology, Heidelberg, Germany. Sunitinib malate (PZ0012) was from Sigma-Aldrich Company
Ltd., Gillingham, UK, dissolved in dimethyl sulfoxide (DMSO), and stored as aliquots at −20 ◦C
until use.
4.2. Tissue Collection
Fresh-frozen primary ccRCC tissue for analysis was obtained from cytoreductive nephrectomy
samples of 23 sunitinib-naive patients with metastatic ccRCC (mccRCC) as part of the Scottish
Collaboration On Translational Research into Renal Cell Cancer (SCOTRRCC) study (UK CRN ID:
12229) [21]. Fresh-frozen primary tumour tissue was also obtained from 27 patients with mccRCC
treated with three cycles of sunitinib (18 weeks) followed by a cytoreductive nephrectomy after
2 weeks off sunitinib as part of the Upfront Sunitinib (SU011248) Therapy Followed by Surgery in
Patients with Metastatic Renal Cancer: A Pilot Phase II Study (SuMR; ClinicalTrials.gov identifier:
NCT01024205); 23 of these patients had adequate tissue for analysis (see Table 1 in [22] for summary
of patient characteristics). Investigations were approved by institutional review boards, and written
informed consent was obtained from each patient. Validation and functional experiments using
human tissue were performed with the written informed consent of patients and ethics approval
(REC reference: 07/Q0108/49). RCC tissue was obtained immediately after surgical excision and
classified according to histological cell type and graded according to the International Society of
Urologic Pathologists (ISUP) [23]. Paraffin sections from each batch of tissue (n = 20 from each tumour
grade and corresponding non-tumour tissue) were stained with H&E, and the diagnosis was verified
independently by an experienced uro-pathologist (AYW).
4.3. Nucleic Acid Extraction
RNA extraction was carried out using the miRNEasy Kit (Qiagen, Manchester, UK) according to
the manufacturer’s protocols.
4.4. Gene-Expression Analysis
As previously described [22], mRNA was amplified using the WT-Ovation FFPE System Version 2
(NuGEN, Redwood City, CA, USA), purified using the Qiaquick PCR Purification Kit (Qiagen, Hilden,
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Germany), biotinylated using the Encore BiotinIL ModuleIL (NuGEN), purified using the minElute
Reaction Cleanup Kit (Qiagen), and quantified using a Bioanalyser 2100 with the RNA 6000 Nano
Kit (Agilent, Santa Clara, CA, USA). cRNA was then hybridized to Human HT-12v3 expression
Beadarrays (Illumina, San Diego, CA, USA) according to the standard protocol for NuGEN-amplified
samples. Gene-expression data were read and normalized with the lump package in R using variance
stabilization and robust spline normalization. Illumina expression data were annotated based upon
ensemble gene annotation (hg19, release 61). Gene-expression data are available via GEO (accession
number GSE65615).
4.5. Regulatory Impact Factor (RIF) Analysis
In brief, RIF establishes different patterns of gene network connectivity (via global assessments
of differential co-expression) across two states (here, sunitinib treated versus untreated RCC tissue
samples). Expressed verbally the algorithm asks the following question: “Which mRNA molecule
is cumulatively the most differentially co-expressed with regard to the highly abundant, highly differentially
expressed genes?” RIF1 and RIF2 are two alternative versions of the same analysis. While RIF1 prioritises
regulators that are consistently the most differentially co-expressed with the highly abundant and
highly DE genes, RIF2 highlights regulators with the most altered abilities to predict the abundance of
DE genes. The outputs of both versions are reported here and the combined information has been
used to generate a functional prediction. In both cases the abundances and differential expressions of
“target” genes are exploited in conjunction with the differential co-expressions of the “regulators” with
respect to those “targets”.
RIF1 and RIF2 were computed as described previously [16,17,24,25]. In this case, the experimental
contrast was sunitinib treated (S) vs. control (C) untreated samples, which resulted in 1279 DE genes
(p-value < 0.001). The entire list of 7350 genes with detectable expression across all S and C samples
was treated as the list of potential regulator genes and the RIF metrics for each regulator in r computed
using the following formulae:
RIF1r =
1
nDE
j=nDE∑
i=1
x j × d j ×DC2rj
and
RIF2r =
1
nDE
j=nDE∑
i=1
[(xSj × rSrj)
2 − (xCj × rCrj)
2
]
where nDE represents the number of DE genes (i.e., nDE = 1279); x j is the average expression of the
j-th DE gene across all samples; xSj is the average expression of the j-th DE gene across the treated
(S) samples; xCj is the average expression of the j-th DE gene across the control (C) samples; d j is the
differential expression of the j-th DE gene in the S vs. C contrast computed as xSj − xCj ; finally, DC2rj is the
square of the differential co-expression between the r-th regulator and the j-th DE gene, and computed
from the difference between rSrj and r
C
rj, the correlation co-expression between the r-th regulator and
the j-th DE gene in the S and C samples, respectively.
4.6. ccRCC and Adjacent Non-Tumour Kidney (NK) Organ Cultures
Organ cultures were developed from ccRCC samples from both tumour and adjacent normal
kidney (NK) tissues from 4 different RCC patients; ≈1.5 × 1 × 0.5 cm were obtained fresh from surgically
excised specimens and developed into organ cultures as previously described [13]. In brief, duplicate
<1 mm3 fragments of tissue from ccRCC and NK were immersed in tissue culture medium (M199
medium containing 10% heat-inactivated fetal calf serum, antibiotics, and 2.2 mM glutamine). Cultures
were either left in media alone (untreated controls; UT) or treated with a dose of sunitinib (25, 50, 100,
or 200 µM) for 1 h at 37 ◦C. A dose response curve was initially carried out, and a dose <25 µM was
used, as previously recommended in cell line experiments, but no significant response to sunitinib was
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seen in organ cultures [24,26]. Cultures were harvested, immediately fixed in 4% paraformaldehyde,
and processed for paraffin-wax embedding.
4.7. Immunohistochemical Staining for PHAX
Paraffin-wax sections of archives tissue of ccRCC grades 1–4 and adjacent NK were immunostained
using our previously described protocol [25]. Antigen retrieval of PHAX involved 2 min in a pressure
cooker containing 0.01 mol/L sodium citrate buffer, pH 6.0. Rabbit anti-human PHAX was incubated
at 1:100 dilution in blocking buffer (10% foetal calf serum in 0.1 mol/L Tris-HCl containing 0.01%
Tween-20) overnight at 4 ◦C. Sections were further incubated at 1:100 with anti-rabbit horseradish
peroxidase-conjugated secondary antibody (Dakocytomation Ltd., Ely, UK) for 1 h at room temperature.
Antibody binding sites were visualised using 3,3′-diaminobenzidine (DAB) solution (Sigma-Aldrich)
containing 0.01% H202, followed by counterstaining in Mayer’s haematoxylin, and viewed using a Nikon
Optiphot-2 microscope (Nikon Corporation, Tokyo, Japan). To quantify the intensity of immunostaining,
images of DAB-stained sections were imported into ImageJ version 1.46f (NIH, Bethesda, MD, USA),
and the average intensity of the entire field was determined using a method previously described [27].
In brief, the digitalised area was submitted to the plug-in “colour deconvolution” using the built-in
vector HDAB, where the staining of haematoxylin and DAB was separated into 3 different panels with
DAB only image, haematoxylin, and background. From this image, the software calculated the area in
mm2, the mean, and the median intensity of DAB, ranging from 0 (black) to 255 (total white). The final
DAB intensity was calculated according to the formula f = 255 − i, where f = final DAB intensity;
i = mean DAB intensity obtained from the software; i ranges from 0 (zero = deep brown, highest
expression), to 255 (total white). When multiple pictures were taken from the same slide, the mean
D-HSCORE was calculated on each. A maximal of 3 regions of interest from the main representative
areas were used.
4.8. Combined Immunofluorescence for PHAX and Cytokeratin or CD31
Sections of ccRCC and NK organ cultures from UT controls and those sunitinib-treated ones
(25, 50, 100, and 200 µM) were subjected to combined-immunostaining for PHAX (1:100 dilution) and
cytokeratin (CK; epithelial marker) or CD31 (endothelial marker) (1:500 dilution). Antibody binding
sites were visualised using secondary antibody-conjugated to Northern Light-498 or Northern Light-557
(R&D Systems, Oxford, UK) (1:100 dilution) and incubated 1 h at room temperature. Hoechst-33342
(1 µg/mL) was used for nuclei detection. Species-specific antisera were used as negative controls.
Slides were dehydrated in ascending series of ethanol, cleared in xylene, and mounted in DePeX
mounts (Sigma-Aldrich, 8 Homefield Rd, Haverhill CB9 8QP, UK). Slides were viewed on a Leica
TCS-SPE confocal microscope (CLSM) (Leica Microsystems, Milton Keynes, UK), and the image for
each fluorophore was acquired sequentially using the same constant acquisition time and settings
rather than simultaneously to avoid crosstalk between channels. Images were then processed in
Adobe Photoshop CS6 software. The following formula was used to calculate the mean corrected total
fluorescence in organ cultures: (CTF) = (integrated density)—(area of selected cell ×mean fluorescent
of background readings). Fluorescence intensity was measured using image J version 1.4v, and data
were transferred to Microsoft Excel and GraphPad Prism v7.0d (LaJolla, CA, USA) for calculations of
means ± SEMs.
4.9. Cell Death and Cell Proliferation Assays
The effect of sunitinib treatment on cell death in ccRCC and NK organ cultures was assessed
using TUNEL as previously described [13,28]. Briefly, UT control and sunitinib-treated organ cultures
were incubated with FITC-dUTP-TUNEL label mix containing TdT-enzyme for 45 min at 37 ◦C. After
thorough washes in MilliQ water, sections were incubated for 10 min at room temperature with Hoechst
33342 for nuclei detection (Molecular Probes, Eugene, OR, USA), mounted in Vectashield Antifade
Mounting Medium (Vector Laboratories Ltd., Peterborough, UK) and viewed on a CLSM.
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The effect of sunitinib on cell proliferation was analysed using antibody to pH3S10 (marker of cell
proliferation) (1:500 dilution) and antibody binding sites detected using secondary antibody-conjugated
to Northern Light-498 or Northern Light-557 containing Hoechst-33342. Slides were rinsed in PBS and
MilliQ water, and mounted before viewing on CLSM.
4.10. Transfection with Specific siRNAs in ccRCC Organ Cultures
ccRCC organ cultures were subjected to siRNA gene knockdown targeting the human PHAX gene.
In brief, tissue were either left UT or transfected with human PHAX siRNA (pool of 3 target-specific
19-25nt siRNAs) (catalogue number sc-106785; Santa Cruz Biotechnology, Heidelberg, Germany)
or with individual siRNAs duplex components of human PHAX siRNA (siRNA-A, siRNA-B, and
siRNA-C) (catalogue number sc-106785-A, B, and C) (all used at 300 nM). Penetration efficiency and the
-target effect of the siRNAs were determined using control siRNA (FITC-conjugated) (catalogue number
sc-36869) and a negative control siRNA (NTsiRNA; a non-gene-specific, “scrambled” siRNA) (catalogue
number sc-37007). Organ cultures were transfected using the transfection reagent Dharmacon Duo
(catalogue number T-2010-01; GE Healthcare Dharmacon, Chalfont St Giles, UK) according to the
manufacturer’s instructions. Cultures were transfected for 72 h (as this time point provided the optimal
knockdown efficiency) followed by treatment with sunitinib for 1 h at 37 ◦C. Cultures were then
harvested, fixed in 4% formaldehyde, and processed for wax-embedding. Sections were subjected to
multiplexed immunofluorescence for PHAX and CD31 followed by incubation with corresponding
secondary antibodies and viewed on CLSM. Cultures incubated with control siRNA (FITC-conjugated)
were also immunostained for CD31.
4.11. Statistical Analysis
The average number of TUNEL-positive (including both tumour and vascular compartment cells)
was counted in 10 random high-power fields of view (×40 magnification) and divided by the total
cell numbers to generate the percentage of positive cells. Counts were carried out on TUNEL stained
organ cultures from 3 different patients’ samples. Similarly, the numbers of pH3S10-positive cells were
counted and divided by the total cell numbers to generate the percentage of positive cells, calculated as
proliferative index. A bar represents a mean ± SEM. Each experiment was repeated at least three times
and the same statistically significant differences between experimental groups were observed in all
three independent experiments, although the absolute values varied. To avoid bias, cell count was
standardised using the microscope stage. A beginning point was chosen at random and the next point
was obtained by moving in a grid pattern across the section. This resulted in data from 10 unbiased
and representative fields per section. Multiple comparisons between groups were analysed using
one-way analysis of variance, followed by Bonferroni post hoc correction. Microsoft Excel 2016 and
GraphPad Prism 7.0d software were used for data processing. Statistical significance was assessed by
the analysis of variance test and a p-value of <0.05 was considered significant.
5. Conclusions
We wished to learn how the therapeutic drug sunitinib mediates its anti-cancer effect in cancer
patients. As a first step in building this understanding, we generated genome-wide gene expression
data for sunitinib treated versus control tumour samples. We then used a differential network approach
called regulatory impact factors to prioritise mRNA that behaves the most differently following drug
treatment. This approach clearly highlighted the mRNA encoding the protein PHAX, despite the fact
this mRNA is not differentially expressed in this context. We then used a combination of experiments
to demonstrate that (a) the PHAX protein is associated with disease progression in clinical samples,
and (b) it can mediate the effectiveness of the drug in an in vitro model of the disease. Overall this
study is an example of how the biological complexity implicit in drug-disease interactions can begin to
be elucidated using computational tools from the post-genomic era.
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Supplementary Materials: The following are available online at http://www.mdpi.com/2079-7737/9/4/74/s1.
Supplementary data file 1: The full RIF output for the 7350 genes which satisfied our criteria for being designated
regulators. RIF1, RIF2, and combined absolute average RIF scores are reported. The absolute average RIF
scores can be ranked to recover PHAX as the most differentially connected mRNA for which we had a gene
annotation. Supplementary data file 2: The basic expression parameters for the 1275 DE genes, including their
differential co-expression values with respect to PHAX. Ranking on the final column prioritises those DE genes
whose differential connectivity with PHAX makes a strong contribution to its extreme RIF score. Figure S1:
Representative confocal images of sections of ccRCC organ culture either left untreated (UT) or treated with
200 µM sunitinib for 1 h at 37 ◦C and immunolabeled with isotype-specific antisera and cytokeratin (CK). No signal
is detected in either of the cultures, which show positive CK staining on tumour cells (arrows). N = 3 per group
with similar results. Original magnification ×40. Figure S2: Combined immunostaining for PHAX and cytokeratin
(CK) in sections of NK organ culture either left untreated (UT) or treated with a dose of sunitinib (25, 50, 100, and
200 µM) for 1 h at 37 ◦C. UT cultures show a rare signal for PHAX also positive for CK (arrows). Also seen are some
PHAX positive infiltrating cells, negative for CK (open arrows). High doses of sunitinib (100 and 200 µM) induce
marked signals of PHAX. Some cells are CK-positive/PHAX-negative (arrowheads). N = 3 per group with similar
results. Original magnification ×40. Figure S3: Combined immunostaining for PHAX and CD31 in sections of NK
organ culture treated with 200 µM sunitinib for 1 h at 37 ◦C show a marked expression of PHAX in blood vessels
mainly in CD31positive endothelial cells (ECs; arrows), infiltrating cells (big arrowheads), and tubular epithelial cells
(t), negative for CD31. N = 3 per group with similar results. Original magnification ×40. Figure S4: Quantification
of fluorescence intensity calculated as corrected total fluorescence (CTF = integrated density—(area of selected cell
×mean fluorescence of background readings) in sections co-immunostaining for PHAX+CD31 in endothelial cells
in organ cultures of ccRCC and NK either left untreated (UT) or treated with different dose of sunitinib (25, 50,
100, or 200 µM). NKoC—*** p < 0.001—vs. UT, 25 or 50 µM; RCCoC—** p < 0.05 vs. UT; *** p < 0.01—vs. 25 or
50 µM; x p < 0.01—vs. 25 or 50 µM; ±p < 0.05—vs. 100 µM. Bars = means + SEMs. N = 3 per group with similar
results. Original magnification ×40.
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DAB Diaminobenzidine
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CTF Corrected total fluorescence
MA Minus average
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TECs Tubular epithelial cells
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